Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo
NAR Cancer · 2026
DOI: 10.1093/narcan/zcag002 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2026. Verfasst von Deling Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.,Suite 415, Bldg A4, 218 Xinghu Street, Suzhou SIP, 215123, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Transforming Growth Factor beta1, Neovascularization, Pathologic, Vascular Endothelial Growth Factor Receptor-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd, Key Technologies Research and Development Program of China.
Abstract (Originalsprache)
Late-stage melanoma can metastasize to organs beyond the skin, such as lungs, liver, brain, and bone, resulting in reduced patient survival time. The incidence of melanoma is currently growing worldwide, and novel therapeutic options are needed to prevent its dissemination and to improve therapeutic results. This paper describes the use of small interfering RNA (siRNA) to silence expression of TGFβ1 and VEGFR2 as an alternative approach for melanoma treatment. These two therapeutic targets have been well-documented in tumor immune modulation and tumor angiogenesis within the tumor microenvironment (TME). Two potent siRNA candidates targeting TGFβ1 or VEGFR2 were identified with 100% identity to sequences of mouse, non-human primate (NHP), and humans. The combination of the two siRNAs was formulated with a clinically validated polypeptide nanoparticle (PNP) carrier. This PNP-packaged siRNA formulation, STP355, administered intravenously in mice bearing syngeneic melanoma tumors, demonstrated silencing of both targets and a reduction in tumor growth. STP355 also reduced tumor weight significantly, without the toxicity observed with cisplatin, resulting in prolonged survival of mice compared with this small molecule. It increased immune cell penetration into TME and reduced metastases to the lung. STP355 was more efficacious than, and somewhat additive with, immune checkpoint inhibitory monoclonal antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.,Suite 415, Bldg A4, 218 Xinghu Street, Suzhou SIP, 215123, China.
- Sirnaomics, Inc., Suite 200, 20511 Seneca Meadows Parkway, Germantown, MD 20876, United States.
ORCID-Profile: David M Evans
Förderung
- Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd
- Key Technologies Research and Development Program of China
Zitieren
APA
Wang, D., Jia, W., Lian, J., Zhang, J., Ren, X., Wang, Z., Liu, W., Zhou, C., Xu, J., Tian, W., Lu, P. Y., & Evans, D. M. (2026). Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo. NAR Cancer. https://doi.org/10.1093/narcan/zcag002
Vancouver
Wang D, Jia W, Lian J, Zhang J, Ren X, Wang Z, et al. Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo. NAR Cancer. 2026. doi:10.1093/narcan/zcag002
BibTeX
@article{Wang2026,
author = {Wang, Deling and Jia, Wanying and Lian, Jinping and Zhang, Jin and Ren, Xiangyu and Wang, Zhiyuan and Liu, Weihui and Zhou, Cheng and Xu, Jun and Tian, Weiwei and Lu, Patrick Y and Evans, David M},
title = {Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo},
journal = {NAR Cancer},
year = {2026},
doi = {10.1093/narcan/zcag002}
}
EUVIMED